BioMarin Pharma (NASDAQ: BMRN) reported Q4 EPS of ($0.47), $0.12 better than the analyst estimate of ($0.59). Revenue for the quarter came in at $230.9 million versus the consensus estimate of $189.01 million.

BioMarin Pharma sees FY2015 revenue of $885-915 million, versus the consensus of $880.6 million.

For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.